This episode of the CBIA BizCast is part one of a two-part discussion on a key issue in Connecticut and across the country— whole genome sequencing.

In this episode Paul Pescatello, CBIA senior counsel and executive director of the Connecticut Bioscience Growth Council speaks with Dr. Tom Defay.

Defay is a computational biologist and Deputy Head Diagnostics Strategy & Development at New Haven-based Alexion Pharmaceuticals, Inc.

He details how the technology is valuable to patients for early diagnosis and treatment, and a cost saver for our healthcare system.

This legislative session a bill to promote expansion of whole genome sequencing, HB 5367, An Act Concerning Medicaid Coverage of Rapid Whole Genome Sequencing for Critically Ill Patients, is before the Connecticut General Assembly.

This is important legislation and it is strongly supported by the CBIA Bioscience Growth Council.